Organization: NeuroVentures Fund

NeurAxon raises US$32 million for pain research

NeurAxon Inc has secured US$32 million in series B financing for further development of its pain therapeutics targeting neuronal nitric oxide synthase (nNOS) for the treatment of neuropathic pain and migraines. Created in 2004, the Toronto-based firm is opening its US headquarters in Waltham MA this fall. Leading the latest financing is Delphi Ventures and…